本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Recursion Pharmaceuticals, Inc.

5.32
-0.5900-9.98%
盘后5.29-0.0300-0.56%18:35 EDT
成交量:5,995.92万
成交额:3.37亿
市值:23.10亿
市盈率:-2.95
高:6.20
开:6.04
低:5.30
收:5.91
52周最高:12.36
52周最低:3.79
股本:4.34亿
流通股本:4.15亿
量比:1.14
换手率:14.45%
股息:- -
股息率:- -
每股收益(TTM):-1.8042
每股收益(LYR):-1.6909
净资产收益率:-86.34%
总资产收益率:-39.08%
市净率:2.51
市盈率(LYR):-3.15

数据加载中...

2024/08/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/06

重要事件披露

Form 8-K - Current report
2024/07/25

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/11

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/10

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/10

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/08

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/06/27

关联方拟减持公告

Form144 | Recursion Pharmaceuticals高管Tina Marriott拟减持6000股,总价约43290美元
2024/06/27

重要事件披露

Form 8-K - Current report
2024/06/25

关联方拟减持公告

Form144|Recursion Pharmaceuticals公司董事Blake Borgeson拟减持11447股,总价约108.8万美元
2024/06/24

重要事件披露

Form 8-K - Current report
2024/06/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/13

SEC问询函

Form CORRESP - Correspondence
2024/06/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/07

重要事件披露

Form 8-K - Current report